Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review

Askari, E; Moghadam, SZ; Wild, D; Delpassand, E; Baldari, S; Nilica, B; Hartrampf, PE; Kong, G; Grana, CM; Walter, MA; Capoccetti, F; Kasi, PM; Strosberg, J

Author(s): Askari, E; Moghadam, SZ; Wild, D; Delpassand, E; Baldari, S; Nilica, B; Hartrampf, PE; Kong, G; Grana, CM; Walter, MA; Capoccetti, F; Kasi, PM; Strosberg, J;
Details: Publication Year 2023-03,Volume 51,Issue #1,Page 22-25
Journal Title: Journal of Nuclear Medicine Technology
Publication Type: Review
Abstract: Merkel cell carcinoma is a rare, aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic Merkel cell carcinoma (mMCC), besides immunotherapy, chemotherapy, and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors. Methods: We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. Results: Thirty-seven patients with mMCC received PRRT (1-5 cycles) with (177)Lu- or (90)Y-labeled somatostatin analogs (cumulative activity, 1.5-30 GBq). Radiographic response was available for 19 of 28 patients who received PRRT alone. Six (31.6%) of 19 patients showed objective responses, from partial to complete, and no severe adverse events were reported. Conclusion: Our analysis supports the use of PRRT in mMCC with sufficient somatostatin receptor uptake, although the quality of the available evidence is low. Prospective clinical trials are already in development and have started accruing in some parts of the world.
Publisher: Society of Nuclear Medicine and Molecular Imaging
Keywords: Humans; *Neuroendocrine Tumors/pathology; *Carcinoma, Merkel Cell/chemically induced/drug therapy; Prospective Studies; Retrospective Studies; Receptors, Somatostatin/metabolism; *Skin Neoplasms/chemically induced/drug therapy; Radioisotopes; Octreotide/therapeutic use; *Organometallic Compounds/therapeutic use; Lu-177; Merkel cell carcinoma; Prrt; Sstr; theranostics
Department(s): Cancer Imaging
PubMed ID: 36195446
Publisher's Version: https://doi.org/10.2967/jnmt.122.264904
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-06-22 07:56:49

Last Modified: 2023-06-22 07:57:28